Introduction. Target Audience. Why Now?. What Does This Book Contribute?. References. Part 1-- Before Prescribing Chapter 1--Pediatric Psychopharmacology Principles. Core Pediatric Psychopharmacology Principles. Additional Pediatric Psychopharmacology Principles.

Organization and Overview. Chapter 2--Conceptual Framework for Prescribing Psychotropic Medications. Rationale for the Conceptual Framework. Group 1 Medications for Attention-Deficit/Hyperactivity Disorder, Anxiety, and Depression Group 2 Medications. Group 3 Medications. References. Chapter 3--Making a Diagnosis. Overview.

Diagnosis of Common Disorders: ADHD, Anxiety Disorders, and Depression. Diagnosis of Common Comorbidities of ADHD, Anxiety Disorders, and Depression. Recognizing Other Psychiatric Disorders. Determine if Medication Is Indicated. Recognize Need for Referral. References. Chapter 4--Before Prescribing. Formulation.

Feedback. Nonmedication Interventions. Informed Consent. Specific Consent Issues. Off-label Prescribing. US Food and Drug Administration Boxed Warnings. Triage for Psychiatric and Social Emergencies. Important Considerations for Safe and Effective Prescribing.

References. Part 2 -- Group 1 Medications for Specific Diagnoses: Attention-Deficit/Hyperactivity Disorder, Anxiety, and Depression Chapter 5--Group 1 Medications for Attention-Deficit/Hyperactivity Disorder. Clinical Comments. General Guidance. Methylphenidate. Amphetamine. Guanfacine. Clonidine.

Atomoxetine. Viloxazine. Summary. References. Chapter 6--Group 1 Medications for Anxiety and Depression . General Guidance. Group 1 Selective Serotonin Reuptake Inhibitors. Group 1 Serotonin and Norepinephrine Reuptake Inhibitor: Duloxetine.

Summary. References. Part 3 -- Group 2 and Group 3 Medications Chapter 7--Group 2 Medications: FDA-Approved Antipsychotics and Mood Stabilizers. Rationale. Antipsychotics. The Mood Stabilizer Lithium. Summary. References.

Chapter 8--Group 3 Medications: Others Commonly Prescribed. Other Antidepressants. Other Antipsychotics. Other Mood Stabilizers. Anxiolytics. Sleep Aids. Future Considerations. References.

Part 4--After Prescribing: Midcourse Corrections Chapter 9--Fine Tuning Treatment. Reevaluate Therapies. Reevaluate Medication. Discontinuing Group 1 Medications. Switching Group 1 Medications. When to Consider Group 2 Antipsychotics or Lithium. When to Consider Group 3 Medications Without FDA Approval for Use in Youth. When to Consider.